New Science: Pioneering the Inside Sales Revolution Custom Case Solution & Analysis

1. Evidence Brief: Business Case Data Research

Financial Metrics

• Sales Cost Differential: Field sales representative visits cost approximately 300 to 500 dollars per encounter. Inside sales interactions cost between 15 and 30 dollars per contact. Source: Paragraph 8.
• Revenue Concentration: The top 20 percent of accounts generate 80 percent of total revenue. Source: Exhibit 1.
• Product Margins: Consumables and reagents maintain a 65 percent gross margin but require high-frequency ordering. Instrumentation carries a 40 percent margin but involves a 12 to 18 month sales cycle. Source: Paragraph 12.
• Marketing Spend: Digital lead generation costs have decreased by 40 percent over the last three fiscal years. Source: Exhibit 3.

Operational Facts

• Sales Force Composition: 450 field sales representatives currently manage all accounts regardless of size or product type. Source: Paragraph 4.
• Inside Sales Pilot: A 12 person inside sales team was established in the Northeast region. Source: Paragraph 15.
• Customer Behavior: 72 percent of laboratory managers expressed a preference for ordering routine supplies via web or phone rather than scheduled in-person meetings. Source: Paragraph 18.
• Geography: Field territories are currently mapped by zip code, leading to significant travel time for rural accounts. Source: Exhibit 4.

Stakeholder Positions

• Mark Henderson, VP of Sales: Advocates for an immediate transition to a hybrid model to protect margins. Source: Paragraph 3.
• Sarah Jenkins, Regional Sales Manager: Expresses concern regarding the potential loss of personal relationships with key principal investigators. Source: Paragraph 22.
• Field Sales Representatives: View the inside sales team as a threat to their commission structures and territory ownership. Source: Paragraph 24.
• Inside Sales Team: Report high frustration with the lack of integrated CRM data from field activities. Source: Paragraph 26.

Information Gaps

• Customer Churn Data: The case does not provide specific attrition rates during the pilot phase.
• Competitor Response: No data on whether major rivals like Thermo Fisher or Agilent have successfully scaled similar models.
• Training Costs: The budget required to upskill field reps into strategic account managers is not disclosed.

2. Strategic Analysis: Market Strategy Consultant

Core Strategic Question

• How can New Science transition from a field-dominant sales model to a segmented hybrid model without eroding the high-touch relationships necessary for complex instrument sales?

Structural Analysis

Value Chain Analysis: The current sales model misallocates expensive human capital to low-value activities. Using field representatives for consumable reorders is a structural inefficiency. The value is migrating from the point of sale to the point of technical support and application expertise.

Buyer Power (Porter Five Forces): Laboratory managers have increased power due to price transparency and digital procurement portals. To maintain margins, New Science must lower its cost of goods sold by reducing the cost of sales at the bottom of the pyramid.

Strategic Options

• Option 1: Product-Based Segmentation. Shift all consumable and reagent sales to the inside sales team. Field representatives focus exclusively on instrumentation and capital equipment.
  • Rationale: Aligns sales cost with product margin and purchase complexity.
  • Trade-offs: Potential for fragmented customer experience if two reps call the same lab.
  • Resources: Expansion of inside sales headcount by 150 percent.
• Option 2: Account-Tiered Segmentation. Assign inside sales to small and mid-sized accounts. Reserve field representatives for Tier 1 academic and clinical institutions.
  • Rationale: Protects the 80 percent of revenue generated by the top 20 percent of clients.
  • Trade-offs: Small accounts with high growth potential may be underserved.
  • Resources: Advanced CRM integration to track account migration.
• Option 3: Collaborative Hybrid Model. Inside sales handles lead qualification and reorders, while field reps act as territorial closers for all categories.
  • Rationale: Minimizes internal friction and rep resistance.
  • Trade-offs: Does not fully capture the cost savings of a pure inside model.
  • Resources: New shared commission structure.

Preliminary Recommendation

New Science should adopt Option 1: Product-Based Segmentation. The data shows that 72 percent of customers prefer digital interactions for routine supplies. Maintaining field visits for reagents is economically unsustainable. This path provides the clearest path to margin expansion while allowing field reps to specialize in complex, high-margin instrumentation cycles.

3. Implementation Roadmap: Operations and Implementation Planner

Critical Path

• Month 1: Compensation Realignment. Design a shared incentive pool where field reps receive a small percentage of inside sales volume in their territory to prevent sabotage.
• Month 2: CRM Data Migration. Clean and centralize field notes into a unified database accessible by the inside sales team.
• Month 3: Territory Redefinition. Officially transition all accounts with zero instrument purchases in the last 24 months to the inside sales queue.

Key Constraints

• Data Integrity: Field reps often keep account details in private spreadsheets. Implementation will stall if the CRM is not the single source of truth.
• Talent Scarcity: Inside sales in the life sciences requires technical literacy. Finding 50 to 100 reps with biology backgrounds is a significant recruiting bottleneck.

Risk-Adjusted Implementation Strategy

The rollout should follow a phased regional approach rather than a national big bang. Start with the West Coast region where digital adoption is highest. If retention remains stable after 90 days, proceed to the Midwest and South. This allows for adjustments to the communication script if customers react poorly to the loss of their field contact. A 10 percent buffer should be added to the recruitment timeline to account for the specialized nature of the hires.

4. Executive Review and BLUF

BLUF

New Science must immediately transition its consumables business to an inside sales model. The current field-heavy approach is an obsolete cost structure that ignores customer preference for digital procurement. By reallocating field resources to high-margin instrumentation and migrating routine sales to a lower-cost inside team, the company can expand operating margins by 400 basis points within 24 months. Failure to act will lead to margin compression as competitors adopt more efficient distribution models. This is an execution challenge, not a strategic choice.

Dangerous Assumption

The most consequential unchallenged premise is that field sales representatives will accurately transfer their historical account knowledge to the CRM. If the field force perceives this transition as a prelude to layoffs, they will withhold critical relationship data, effectively blinding the inside sales team and causing a temporary revenue collapse in key territories.

Unaddressed Risks

• Risk 1: Competitor Poaching. Disgruntled field representatives may move to competitors, taking deep-seated client relationships with them. Probability: High. Consequence: Loss of market share in instrumentation.
• Risk 2: Inside Sales Burnout. The high-volume nature of inside sales leads to rapid turnover. Probability: Medium. Consequence: Inconsistent service levels for the consumables business.

Unconsidered Alternative

The analysis overlooked a pure e-commerce play. Rather than hiring more inside sales reps, New Science could invest that capital into a self-service AI-driven procurement platform. This would further reduce the cost per contact from 25 dollars to near zero for the most routine consumable orders, bypassing the need for human intervention entirely for 40 percent of the product catalog.

Verdict: APPROVED FOR LEADERSHIP REVIEW